TR200100278T2 - Oksazolo, tiazolo ve selenazolo [4,5-c] -Kinolin-4-Aminler ve bunların analogları. - Google Patents

Oksazolo, tiazolo ve selenazolo [4,5-c] -Kinolin-4-Aminler ve bunların analogları.

Info

Publication number
TR200100278T2
TR200100278T2 TR2001/00278T TR200100278T TR200100278T2 TR 200100278 T2 TR200100278 T2 TR 200100278T2 TR 2001/00278 T TR2001/00278 T TR 2001/00278T TR 200100278 T TR200100278 T TR 200100278T TR 200100278 T2 TR200100278 T2 TR 200100278T2
Authority
TR
Turkey
Prior art keywords
selenazolo
oxazolo
thiazolo
kinolin
analogs
Prior art date
Application number
TR2001/00278T
Other languages
English (en)
Turkish (tr)
Inventor
F. Gerster John
J. Lindstrom Kyle
J. Marszalek Gregory
A. Merrill Bryon
W. Mickelson John
J. Rice Michael
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Publication of TR200100278T2 publication Critical patent/TR200100278T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
    • C07D517/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
TR2001/00278T 1998-07-28 1999-07-28 Oksazolo, tiazolo ve selenazolo [4,5-c] -Kinolin-4-Aminler ve bunların analogları. TR200100278T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9434698P 1998-07-28 1998-07-28
US09/361,544 US6110929A (en) 1998-07-28 1999-07-27 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof

Publications (1)

Publication Number Publication Date
TR200100278T2 true TR200100278T2 (tr) 2001-08-21

Family

ID=26788753

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00278T TR200100278T2 (tr) 1998-07-28 1999-07-28 Oksazolo, tiazolo ve selenazolo [4,5-c] -Kinolin-4-Aminler ve bunların analogları.

Country Status (24)

Country Link
US (9) US6110929A (enExample)
EP (1) EP1100802B1 (enExample)
JP (1) JP4662630B2 (enExample)
KR (1) KR100696349B1 (enExample)
CN (1) CN1147493C (enExample)
AT (2) ATE320435T1 (enExample)
AU (1) AU748050B2 (enExample)
BR (1) BR9912448A (enExample)
CA (1) CA2338504C (enExample)
CZ (1) CZ291753B6 (enExample)
DE (2) DE69911622T2 (enExample)
DK (1) DK1100802T3 (enExample)
ES (2) ES2260554T3 (enExample)
HU (1) HUP0103137A3 (enExample)
IL (1) IL140822A0 (enExample)
MX (1) MXPA01000757A (enExample)
NO (1) NO20010497L (enExample)
NZ (1) NZ509420A (enExample)
PL (1) PL347590A1 (enExample)
PT (2) PT1380587E (enExample)
RU (1) RU2244717C2 (enExample)
SK (1) SK1402001A3 (enExample)
TR (1) TR200100278T2 (enExample)
WO (1) WO2000006577A1 (enExample)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (sk) 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
AU2006216669A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
WO2002046749A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005501550A (ja) * 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
EP1478327B1 (en) * 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
EP1487486B1 (en) * 2002-03-19 2009-01-14 PowderJect Research Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
AU2003216851B2 (en) * 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
CA2488801A1 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
US6818650B2 (en) * 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
CA2517528A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006519877A (ja) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー １−アミノ１ｈ−イミダゾキノリン
CA2518282C (en) * 2003-03-13 2012-11-06 3M Innovative Properties Company Methods of improving skin quality
JP2006523212A (ja) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー 皮膚病変の診断方法
US7179253B2 (en) 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1615665A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20040214851A1 (en) * 2003-04-28 2004-10-28 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AU2004261243A1 (en) * 2003-07-31 2005-02-10 3M Innovative Properties Company Bioactive compositions comprising triazines
AU2004264336B2 (en) * 2003-08-05 2010-12-23 3M Innovative Properties Company Formulations containing an immune response modifier
AU2004266641A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
WO2005018555A2 (en) * 2003-08-14 2005-03-03 3M Innovative Properties Company Lipid-modified immune response modifiers
CA2536249A1 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
CA2551075A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
MXPA06002408A (es) * 2003-09-02 2006-06-20 3M Innovative Properties Co Metodos relacionados al tratamiento de condiciones asociadas a la mucosa.
US20050054665A1 (en) * 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
CA2547085A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
CA2549216A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
EP1699792A1 (en) * 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005089317A2 (en) 2004-03-15 2005-09-29 3M Innovative Properties Company Immune response modifier formulations and methods
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
JP2008505857A (ja) * 2004-04-28 2008-02-28 スリーエム イノベイティブ プロパティズ カンパニー 粘膜ワクチン接種のための組成物および方法
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259907A1 (en) * 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
PL1789042T3 (pl) * 2004-09-02 2012-09-28 3M Innovative Properties Co Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
BRPI0515316A (pt) * 2004-09-14 2008-07-15 Chiron Corp compostos de imidazoquinolina
US20070243215A1 (en) * 2004-10-08 2007-10-18 Miller Richard L Adjuvant for Dna Vaccines
ATE538124T1 (de) 2004-11-12 2012-01-15 Bristol Myers Squibb Co Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
WO2006053166A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company 8h-imidazo[4,5-d]thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
EP1819364A4 (en) * 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
NZ556399A (en) * 2004-12-30 2009-03-31 Takeda Pharmaceutical 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US8461174B2 (en) * 2004-12-30 2013-06-11 3M Innovative Properties Company Treatment for cutaneous metastases
JP2008526752A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物の多経路投与
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2006086449A2 (en) * 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
WO2006098852A2 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
AU2006223148A1 (en) 2005-03-14 2006-09-21 3M Innovative Properties Company Method of treating actinic keratosis
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (ja) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー 免疫活性化組成物
WO2007011777A2 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US8258191B2 (en) * 2005-10-31 2012-09-04 Coloplast A/S Topical skin barriers and methods of evaluation thereof
WO2007052058A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
RU2425834C2 (ru) * 2005-11-08 2011-08-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ТИАЗОЛО[4,5-c]ПИРИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ mGluR5
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
JP2009529539A (ja) * 2006-03-07 2009-08-20 エンダセア， インコーポレイテッド 呼吸器障害を治療するための方法および組成物
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
CA2646539A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
AU2007275815A1 (en) * 2006-07-18 2008-01-24 Wirra Ip Pty. Ltd. Immune response modifier formulations
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US8124096B2 (en) * 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US20100028420A1 (en) * 2006-12-22 2010-02-04 3M Innovative Properties Company Controlled release composition and process
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2217236A1 (en) * 2007-11-02 2010-08-18 Yaupon Therapeutics, Inc. Use of lobeline epimers in the treatment of central nervous system diseases, pathologies, and drug abuse
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
SG196837A1 (en) 2009-01-20 2014-02-13 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
DK2411815T3 (en) 2009-03-24 2015-11-30 Transgene Sa Biomarker MONITORING OF PATIENTS
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
DK2419728T3 (da) 2009-04-17 2014-02-03 Transgene Sa Biomarkør til at overvåge patienter
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
RU2552292C2 (ru) 2009-07-10 2015-06-10 Трансжене Са Биомаркер для отбора пациентов и связанные с ним способы
SI3178490T1 (sl) 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
HRP20141270T1 (xx) 2009-07-16 2015-03-13 Novartis Ag Detoksificirani imunogeni escherichie coli
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
HRP20170433T1 (hr) 2010-08-17 2017-05-05 3M Innovative Properties Company Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
CA2820851A1 (en) * 2010-12-09 2012-06-14 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
HRP20190791T1 (hr) 2011-01-26 2019-06-28 Glaxosmithkline Biologicals Sa Režim imuniziranja protiv rsv
MY170941A (en) 2011-04-08 2019-09-19 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
WO2012167081A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
MX2014004814A (es) * 2011-10-21 2014-05-27 Glaxosmithkline Llc Compuestos y metodos para mejorar las respuestas inmunes innatas.
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
IN2014MN00862A (enExample) 2011-11-09 2015-04-17 Janssen R & D Ireland
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
AU2013288600B2 (en) 2012-07-13 2017-06-29 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014023813A1 (en) 2012-08-10 2014-02-13 Janssen R&D Ireland Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX365114B (es) 2012-10-10 2019-05-23 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidinicos para el tratamiento de infecciones viricas y otras enfermedades.
MY171115A (en) 2012-11-16 2019-09-26 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
CN105025854A (zh) 2013-01-07 2015-11-04 宾夕法尼亚大学董事会 治疗皮肤t细胞淋巴瘤的组合物和方法
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
KR20150136077A (ko) 2013-03-10 2015-12-04 페리테크 파마 엘티디. 국소 조성물 및 국소 질환의 치료 방법
ES2625456T3 (es) 2013-03-29 2017-07-19 Janssen Sciences Ireland Uc Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas
JP6377139B2 (ja) 2013-05-24 2018-08-22 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
PL3030563T3 (pl) 2013-06-27 2018-01-31 Janssen Sciences Ireland Uc Pochodne pirolo [3,2-d] pirymidyny do leczenia zakażeń wirusowych i innych chorób
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
CR20160214A (es) 2013-11-05 2016-10-11 3M Innovative Properties Co Formulaciones de inyección con base en aceite de sésamo
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
US10421971B2 (en) 2014-01-15 2019-09-24 The University Of Chicago Anti-tumor therapy
EP3122378B1 (en) 2014-03-26 2019-12-11 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
KR102582563B1 (ko) 2014-06-20 2023-09-25 재단법인 한국파스퇴르연구소 항감염 화합물
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016180274A1 (zh) * 2015-05-09 2016-11-17 江苏新元素医药科技有限公司 用于治疗或预防乳腺癌的化合物
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
CN107922416B (zh) 2015-08-31 2021-07-02 3M创新有限公司 含有取代的胍基团的咪唑并[4,5-c]环化合物
EP3344622B1 (en) 2015-08-31 2021-07-07 3M Innovative Properties Company Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
US10526309B2 (en) 2015-10-02 2020-01-07 The University Of North Carolina At Chapel Hill Pan-TAM inhibitors and Mer/Axl dual inhibitors
TWI812584B (zh) 2015-10-30 2023-08-21 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
AU2017268175B2 (en) 2016-05-16 2023-02-23 Access To Advanced Health Institute PEGylated liposomes and methods of use
HUE059605T2 (hu) 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
CA3034553A1 (en) 2016-08-26 2018-03-01 3M Innovative Properties Company Fused [1,2]imidazo[4,5-c] ring compounds substituted with guanidino groups
KR102497742B1 (ko) 2016-08-30 2023-02-10 다나-파버 캔서 인스티튜트 인크. 약물 전달 조성물 및 그의 용도
EA038646B1 (ru) 2016-09-29 2021-09-28 Янссен Сайенсиз Айрлэнд Анлимитед Компани Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
BR112019009469A2 (pt) 2016-11-09 2019-07-30 Pulmotect Inc métodos e composições para a modulação imunológica adaptativa
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
US10766896B2 (en) 2017-03-01 2020-09-08 3M Innovative Properties Company Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
EP3710059A1 (en) 2017-11-14 2020-09-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
CA3092545A1 (en) 2018-02-28 2019-09-06 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019209896A1 (en) * 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR20230146098A (ko) 2018-05-23 2023-10-18 화이자 인코포레이티드 GUCY2c에 특이적인 항체 및 이의 용도
DK3797121T3 (da) 2018-05-23 2024-07-08 Pfizer Antistoffer, der er specifikke for CD3, og anvendelser deraf
EP3802536B1 (en) 2018-05-24 2022-07-13 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020109898A1 (en) 2018-11-26 2020-06-04 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
CN113924297A (zh) 2019-06-06 2022-01-11 3M创新有限公司 N-1支链烷基取代的咪唑并[4,5-c]喹啉化合物、组合物和方法
CN113906027A (zh) 2019-06-12 2022-01-07 3M创新有限公司 具有N-1支链基团的苯乙基取代的咪唑并[4,5-c]喹啉化合物
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
PE20230160A1 (es) 2019-12-17 2023-02-01 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos
JP2023533011A (ja) 2020-07-08 2023-08-01 スリーエム イノベイティブ プロパティズ カンパニー Ｎ－１分岐イミダゾキノリン、そのコンジュゲート、及び方法
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
JP2023533793A (ja) 2020-07-17 2023-08-04 ファイザー・インク 治療用抗体およびそれらの使用
JP2023554377A (ja) 2020-12-16 2023-12-27 スリーエム イノベイティブ プロパティズ カンパニー Ｎ－１分岐イミダゾキノリン、そのコンジュゲート、及び方法
WO2023111726A1 (en) 2021-12-14 2023-06-22 3M Innovative Properties Company N-1 triazole substituted imidazoquinolines, conjugates thereof, and methods
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2288521A1 (fr) * 1974-10-25 1976-05-21 Merck Patent Gmbh Nouvelles penicillines et procede pour leur preparation
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
US4131677A (en) * 1975-05-02 1978-12-26 Merck & Co., Inc. Anti-inflammatory oxazolo [5,4-b]pyridines
US4275065A (en) * 1979-06-21 1981-06-23 American Home Products Corporation Modulating the immune response with 2-substituted-3-hydroxythiazolo[2,3-b]be
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
HU197019B (en) * 1985-11-12 1989-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing thiqzolo (4,5-c) quinoline derivatives and pharmaceuticals comprising same
HU196308B (en) * 1985-11-12 1988-11-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions containing 2-methyl-thiazolo/4,5-c/quinoline as active component
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US5266376A (en) * 1989-12-25 1993-11-30 Toray Industries, Inc. Magnetic recording medium
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
CA2167042A1 (en) * 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
AU743901B2 (en) * 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors
FR2761071B1 (fr) * 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
SK287112B6 (sk) * 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Also Published As

Publication number Publication date
RU2244717C2 (ru) 2005-01-20
HK1038228A1 (en) 2002-03-08
ATE320435T1 (de) 2006-04-15
US20040122041A1 (en) 2004-06-24
ATE250612T1 (de) 2003-10-15
US20030045545A1 (en) 2003-03-06
DE69911622T2 (de) 2004-06-17
JP2002524392A (ja) 2002-08-06
NO20010497L (no) 2001-03-27
KR100696349B1 (ko) 2007-03-20
US6627640B2 (en) 2003-09-30
KR20010085309A (ko) 2001-09-07
WO2000006577A1 (en) 2000-02-10
NZ509420A (en) 2003-08-29
US6110929A (en) 2000-08-29
AU5133199A (en) 2000-02-21
US6440992B1 (en) 2002-08-27
US6677334B2 (en) 2004-01-13
EP1100802B1 (en) 2003-09-24
US20030065006A1 (en) 2003-04-03
US6809203B2 (en) 2004-10-26
ES2203160T3 (es) 2004-04-01
EP1100802A1 (en) 2001-05-23
DE69930327T2 (de) 2006-12-07
HUP0103137A3 (en) 2002-06-28
NO20010497D0 (no) 2001-01-29
CA2338504A1 (en) 2000-02-10
BR9912448A (pt) 2001-10-09
CA2338504C (en) 2011-03-08
CZ2001327A3 (cs) 2001-08-15
DE69911622D1 (de) 2003-10-30
US20030064968A1 (en) 2003-04-03
CN1320126A (zh) 2001-10-31
MXPA01000757A (es) 2002-04-08
US20050026943A1 (en) 2005-02-03
US20030195224A1 (en) 2003-10-16
CZ291753B6 (cs) 2003-05-14
US20020072528A1 (en) 2002-06-13
CN1147493C (zh) 2004-04-28
HUP0103137A2 (hu) 2002-01-28
US6323200B1 (en) 2001-11-27
PL347590A1 (en) 2002-04-08
US7148232B2 (en) 2006-12-12
IL140822A0 (en) 2002-02-10
DK1100802T3 (da) 2004-02-09
PT1100802E (pt) 2004-02-27
DE69930327D1 (de) 2006-05-11
US6703402B2 (en) 2004-03-09
US6627638B2 (en) 2003-09-30
AU748050B2 (en) 2002-05-30
JP4662630B2 (ja) 2011-03-30
SK1402001A3 (en) 2001-08-06
PT1380587E (pt) 2006-08-31
ES2260554T3 (es) 2006-11-01

Similar Documents

Publication Publication Date Title
TR200100278T2 (tr) Oksazolo, tiazolo ve selenazolo [4,5-c] -Kinolin-4-Aminler ve bunların analogları.
IT8621411A0 (it) Padiglione smontabile particolarmente per il ricovero temporaneo di persone.
ATE182332T1 (de) Pyrazolo und pyrrolopyridine
FI95472B (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
SG148201A1 (en) Substituted imidazo ring systems and methods
WO2005079195A3 (en) Pyrazolopyridines and analogs thereof
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
FI963070A0 (fi) Klooripyrimidiinivälituotteita
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
AP2000001881A0 (en) 2-(Purine-9-YL)-tetrahydrofuran-3,4 4-diol derivatives.
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DK1390371T3 (da) Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
EP0204989A3 (en) Use of penicillamine in the treatment of immune deficiency diseases
SE0100684D0 (sv) New subject-matter
UY27312A1 (es) Nuevos heterociclos 3
IT8721560A0 (it) Procedimento per la purificazione di interferone.
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
NO982151L (no) Hemoregulatoriske forbindelser
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.
ITVI920198A1 (it) Ciclo di lavorazione per la produzione di pelli tipo nabuk